专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

US20120142028A1 BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS 审中-公开
标题翻译：生物标志物预防抗癌生长因子受体激酶激酶抑制剂
公开(公告)号：US20120142028A1
公开(公告)日：2012-06-07
申请号：US13264786
申请日：2010-04-15
申请人： Frank C. Richardson , G. David Young , Julie L. Wolf , Regina M. Sennello
发明人： Frank C. Richardson , G. David Young , Julie L. Wolf , Regina M. Sennello
IPC分类号： G01N33/566
CPC分类号： G01N33/57484 , G01N2333/705 , G01N2800/52
摘要： The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. These methods are based on the surprising discovery that the effectiveness of treatment with an EGFR kinase inhibitor is predicted by whether a patient's tumor cells express a high or a low level of the biomarkers vimentin and E-cadherin, such that patients whose tumors express a high level of at least one of the biomarkers vimentin and E-cadherin have a longer overall survival and progression free survival than patients whose tumors express a low level of both vimentin and E-cadherin. The present invention further provides a method for treating tumors or tumor metastases in a patient, comprising the steps of diagnosing a patient's likely responsiveness to an EGFR kinase inhibitor by assessing whether tumor cells express a high level of at least one of the biomarkers vimentin and E-cadherin, and administering to said patient a therapeutically effective amount of an EGFR kinase inhibitor (e.g. erlotinib), particularly when effectiveness of the inhibitor is predicted.
摘要翻译：本发明提供用于预测用EGFR激酶抑制剂治疗癌症患者的有效性的诊断方法。这些方法基于惊人的发现，即用EGFR激酶抑制剂治疗的有效性是通过患者的肿瘤细胞表达高水平或低水平的生物标志物波形蛋白和E-钙粘蛋白来预测的，使得肿瘤表达高的患者至少一种生物标志物波形蛋白和E-钙粘蛋白的水平比肿瘤表达低水平的波形蛋白和E-钙粘蛋白的患者具有更长的总生存期和无进展生存期。本发明进一步提供了一种治疗患者肿瘤或肿瘤转移的方法，包括以下步骤：通过评估肿瘤细胞是否表达高水平的至少一种生物标志物波形蛋白和E来诊断患者对EGFR激酶抑制剂的可能反应性 - 加珠蛋白，并且向所述患者施用治疗有效量的EGFR激酶抑制剂（例如厄洛替尼），特别是当预测该抑制剂的有效性时。

IPRDB

热门服务

关于我们

友情链接

联系方式